Effect of CYP3A inhibition on vesnarinone metabolism in humans

Christoph Wandel; Chim C. Lang; Doug C. Cowart; Armand F. Girard; Steve Bramer; David A. Flockhart; Alastair J. J. Wood

doi:10.1016/S0009-9236(98)90101-1

Effect of CYP3A inhibition on vesnarinone metabolism in humans

Christoph Wandel
, Chim C. Lang
, Doug C. Cowart
, Armand F. Girard
, Steve Bramer
, David A. Flockhart
, Alastair J. J. Wood

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

Abstract

To identify the cytochrome P450 (CYP) enzymes involved in the conversion of vesnarinone to it main primary metabolite OPC-18692 and to investigate the effect of CYP3A inhibition on the pharmacokinetics of vesnarinone in vivo.

Original language	English
Pages (from-to)	506-511
Number of pages	6
Journal	Clinical Pharmacology & Therapeutics
Volume	63
Issue number	5
DOIs	https://doi.org/10.1016/S0009-9236(98)90101-1
Publication status	Published - 1998
Event	98th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics - Town and Country Hotel, San Diego, California, United States Duration: 5 Mar 1997 → 8 Mar 1997

Access to Document

10.1016/S0009-9236(98)90101-1

Cite this

@article{1c59ee9412d349bcb598a31ca884f8dd,

title = "Effect of CYP3A inhibition on vesnarinone metabolism in humans",

abstract = "To identify the cytochrome P450 (CYP) enzymes involved in the conversion of vesnarinone to it main primary metabolite OPC-18692 and to investigate the effect of CYP3A inhibition on the pharmacokinetics of vesnarinone in vivo.",

author = "Christoph Wandel and Lang, \{Chim C.\} and Cowart, \{Doug C.\} and Girard, \{Armand F.\} and Steve Bramer and Flockhart, \{David A.\} and Wood, \{Alastair J. J.\}",

year = "1998",

doi = "10.1016/S0009-9236(98)90101-1",

language = "English",

volume = "63",

pages = "506--511",

journal = "Clinical Pharmacology \& Therapeutics",

issn = "0009-9236",

publisher = "Wiley",

number = "5",

note = "98th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics ; Conference date: 05-03-1997 Through 08-03-1997",

}

TY - JOUR

T1 - Effect of CYP3A inhibition on vesnarinone metabolism in humans

AU - Wandel, Christoph

AU - Lang, Chim C.

AU - Cowart, Doug C.

AU - Girard, Armand F.

AU - Bramer, Steve

AU - Flockhart, David A.

AU - Wood, Alastair J. J.

PY - 1998

Y1 - 1998

N2 - To identify the cytochrome P450 (CYP) enzymes involved in the conversion of vesnarinone to it main primary metabolite OPC-18692 and to investigate the effect of CYP3A inhibition on the pharmacokinetics of vesnarinone in vivo.

AB - To identify the cytochrome P450 (CYP) enzymes involved in the conversion of vesnarinone to it main primary metabolite OPC-18692 and to investigate the effect of CYP3A inhibition on the pharmacokinetics of vesnarinone in vivo.

U2 - 10.1016/S0009-9236(98)90101-1

DO - 10.1016/S0009-9236(98)90101-1

M3 - Article

C2 - 9630823

SN - 0009-9236

VL - 63

SP - 506

EP - 511

JO - Clinical Pharmacology & Therapeutics

JF - Clinical Pharmacology & Therapeutics

IS - 5

T2 - 98th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics

Y2 - 5 March 1997 through 8 March 1997

ER -

Effect of CYP3A inhibition on vesnarinone metabolism in humans

Abstract

Access to Document

Fingerprint

Cite this